Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404
Help Center
Careers
Contact

Frontotemporal Disorder Treatment Market

Frontotemporal Disorder Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Pharmacological Treatment, Non-Pharmacological Treatment), By Drug Class (Selective Serotonin Reuptake Inhibitors (SSRIs), Atypical Antipsychotics, Tricyclic Antidepressants, Glutamate Modulators, Investigational Disease-Modifying Therapies), By Disease Type (Behavioral Variant FTD (bvFTD), Primary Progressive Aphasia (PPA), FTD with Motor Neuron Disease (FTD-MND)), Forecast Period (2026-2035)

Published: Jul 2026 | Report Code: OMR2022159 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Frontotemporal disorder treatment market was valued at $414.1 million in 2025 and is projected to reach $785.4 million by 2035, growing at a CAGR of 6.8% during 2026 to 2035. The market growth is primarily driven by the increasing prevalence of neurodegenerative disorders and rising awareness regarding early diagnosis and treatment options.

According to the World Health Organization (WHO), neurological disorders account for a significant proportion of global disease burden, contributing to nearly 10% of total disability-adjusted life years (DALYs) globally. Frontotemporal disorders, although less prevalent than Alzheimer’s disease, are among the leading causes of early-onset dementia, particularly affecting individuals under the age of 65.

The growing demand for effective symptomatic treatments, including antidepressants and antipsychotics, is supporting market expansion. Additionally, advancements in neuroscience research and increasing investment in disease-modifying therapies are expected to create new growth opportunities. Major end-use sectors include hospitals, neurology clinics, and long-term care facilities, where treatment demand is steadily rising due to increasing patient diagnosis rates.

Market Dynamics

Rising Prevalence of Neurodegenerative Disorders Driving Market Growth

The increasing global burden of neurodegenerative diseases is a key driver of the Frontotemporal Disorder Treatment Market. According to the World Health Organization (WHO), over 55 million people globally are living with dementia, with nearly 10 million new cases reported annually. While frontotemporal disorders represent a smaller share, they are among the most common causes of early-onset dementia, leading to significant clinical demand.

Growing awareness regarding early diagnosis and improved access to healthcare infrastructure are further accelerating treatment adoption. Pharmaceutical companies are actively investing in CNS drug development, particularly focusing on symptomatic therapies such as SSRIs and antipsychotics. Additionally, regulatory support from organizations like the U.S. Food and Drug Administration (FDA) for orphan drug designation is encouraging innovation in rare neurological disorders. Strategic collaborations and clinical trial expansions between 2025 and 2026 are also enhancing pipeline development and market penetration.

Limited Disease-Modifying Therapies and High Treatment Complexity Restraining Growth

Despite steady growth, the market faces significant challenges due to the absence of approved disease-modifying therapies for frontotemporal disorders. Most available treatments focus on symptom management rather than addressing underlying disease pathology, limiting long-term clinical outcomes.

High research and development costs associated with neurodegenerative drug discovery present another barrier. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the average cost of developing a new drug exceeds $3.13 billion, with neurological drugs facing higher failure rates in clinical trials. Additionally, diagnostic complexity and overlapping symptoms with other dementias often lead to delayed or incorrect diagnoses, reducing treatment efficiency. Supply chain challenges, particularly for specialized CNS drugs, and pricing pressures in generic drug markets further impact profitability. However, ongoing innovation in biomarker-based diagnostics and gene therapy research is expected to gradually address these limitations.

Market Segmentation

  • Based on the treatment type, the market is segmented into pharmacological treatment and non-pharmacological treatment.
  • Based on the drug class, the market is segmented into selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics, tricyclic antidepressants, glutamate modulators, and investigational disease-modifying therapies.
  • Based on the disease type, the market is segmented into behavioral variant FTD (bvFTD), primary progressive aphasia (PPA), and FTD with motor neuron disease (FTD-MND).

Pharmacological Treatment Segment Leads the Market

The pharmacological treatment segment dominates the frontotemporal disorder treatment market due to its widespread use in managing behavioral and psychological symptoms. Drugs such as SSRIs and atypical antipsychotics are commonly prescribed to control mood disturbances, aggression, and cognitive decline associated with FTD. Between 2022 and 2026, pharmaceutical companies have focused on expanding their CNS portfolios, leading to increased drug availability and improved patient access. The reliance on drug-based therapies in hospital and clinical settings further strengthens this segment’s position. Additionally, the relatively low cost and high availability of generic drugs contribute to higher adoption rates globally.

Investigational Disease-Modifying Therapies Segment to Record Strong Growth

The investigational disease-modifying therapies segment is expected to witness the fastest growth during the forecast period. Increasing research into tau protein and TDP-43 pathology is driving innovation in targeted therapies aimed at slowing disease progression. Pharmaceutical and biotechnology companies are investing heavily in clinical trials and gene therapy approaches. According to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), global R&D spending in the pharmaceutical sector exceeds $200 billion annually, with a growing share allocated to neurological disorders. Emerging technologies such as precision medicine and biomarker-based diagnostics are further accelerating this segment’s growth, making it a key area of future market expansion.

Regional Outlook

The global frontotemporal disorder treatment market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the frontotemporal disorder treatment market due to its advanced healthcare infrastructure and high healthcare spending. According to the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare expenditure exceeded $4.5 trillion in 2022, supporting extensive access to neurological treatments. Strong presence of leading pharmaceutical companies and ongoing clinical trials contribute to market growth. Additionally, regulatory support from the FDA and increasing awareness regarding early-onset dementia are driving treatment adoption. The availability of specialized neurology centers further enhances patient diagnosis and management.

China to Record Strong Growth

China is expected to witness significant growth in the frontotemporal disorder treatment market due to expanding healthcare infrastructure and increasing investment in pharmaceutical manufacturing. According to the OECD, China’s healthcare spending has been growing at over 8% annually, reflecting strong government support. Rising awareness of neurological disorders and improving access to healthcare services are key growth drivers. Additionally, increasing domestic production of generic drugs and government initiatives to enhance drug accessibility are boosting market expansion. Infrastructure development and research collaborations are further strengthening China’s position in the global market.

Market Player Outlook

The frontotemporal disorder treatment market is moderately fragmented, with a mix of global pharmaceutical companies and emerging biotechnology firms competing for market share. Innovation is primarily focused on symptomatic treatments and pipeline development for disease-modifying therapies. Companies are investing in R&D, strategic collaborations, and clinical trials to strengthen their market position. The leading players, such as Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Viatris Inc., Johnson & Johnson (Janssen Pharmaceuticals), and Eisai Co., Ltd., are actively expanding their CNS drug portfolios. These companies leverage strong distribution networks and established brand presence to maintain a competitive advantage. Additionally, partnerships with research institutions and biotechnology firms are accelerating innovation and product development.

Recent Developments

  • In March 2026, AviadoBio advanced its position in the frontotemporal disorder treatment market by initiating the fourth dose-escalation cohort of its Phase 1/2 ASPIRE-FTD trial for AVB-101, a gene therapy targeting FTD-GRN patients. The program has demonstrated encouraging early biomarker improvements and a favorable safety profile, supporting further clinical development.
  • In October 2025, Anavex Life Sciences Corp. advanced its presence in the frontotemporal disorder treatment market through promising clinical progress of its oral candidate blarcamesine. The therapy demonstrated significant long-term cognitive benefits, reduced disease progression, and showed a favorable safety profile in extended trials.

The Report Covers

  • Market value data analysis of 2025 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global frontotemporal disorder treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.
  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Global Frontotemporal Disorder Treatment Market Sales Analysis – Treatment Type | Drug Class | Disease Type ($ Million)
  • Frontotemporal Disorder Treatment Market Sales Performance of Top Countries

1.1 Research Methodology

  • Primary Research Approach
  • Secondary Research Approach

1.2 Market Snapshot

  1. Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

2.2.1 Key Frontotemporal Disorder Treatment Market Trends

2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Frontotemporal Disorder Treatment Market

2.3.1 Competitive Rivalry

2.3.2 Threat of New Entrants

2.3.3 Bargaining Power of Suppliers

2.3.4 Bargaining Power of Buyers

2.3.5 Threat of Substitutes

  1. Market Determinants

3.1 Market Drivers

3.1.1 Drivers For Global Frontotemporal Disorder Treatment Market: Impact Analysis

3.2 Market Pain Points and Challenges

3.2.1 Restraints For Global Frontotemporal Disorder Treatment Market: Impact Analysis

3.3 Market Opportunities

3.3.1 Opportunities For Global Frontotemporal Disorder Treatment Market: Impact Analysis

  1. Competitive Landscape

4.1 Competitive Dashboard – Frontotemporal Disorder Treatment Market Revenue and Share by Manufacturers

  • Frontotemporal Disorder Treatment Product Comparison Analysis
  • Top Market Player Ranking Matrix

4.2 Key Company Analysis

4.2.1 Lundbeck A/S

4.2.1.1 Overview

4.2.1.2 Product Portfolio

4.2.1.3 Financial Analysis

4.2.1.4 SWOT Analysis

4.2.1.5 Business Strategy

4.2.2 Otsuka Pharmaceutical Co., Ltd.

4.2.2.1 Overview

4.2.2.2 Product Portfolio

4.2.2.3 Financial Analysis

4.2.2.4 SWOT Analysis

4.2.2.5 Business Strategy

4.2.3 Viatris Inc.

4.2.3.1 Overview

4.2.3.2 Product Portfolio

4.2.3.3 Financial Analysis

4.2.3.4 SWOT Analysis

4.2.3.5 Business Strategy

4.2.4 Johnson & Johnson (Janssen Pharmaceuticals)

4.2.4.1 Overview

4.2.4.2 Product Portfolio

4.2.4.3 Financial Analysis

4.2.4.4 SWOT Analysis

4.2.4.5 Business Strategy

4.2.5 Eisai Co., Ltd.

4.2.5.1 Overview

4.2.5.2 Product Portfolio

4.2.5.3 Financial Analysis

4.2.5.4 SWOT Analysis

4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

4.3.1 Merger and Acquisition

4.3.2 Product Launch

4.3.3 Partnership And Collaboration

  1. Global Frontotemporal Disorder Treatment Market Sales Analysis by Treatment Type ($ Million)

5.1 Pharmacological Treatment

5.2 Non-Pharmacological Treatment

  1. Global Frontotemporal Disorder Treatment Market Sales Analysis by Drug Class ($ Million)

6.1 Selective Serotonin Reuptake Inhibitors (SSRIs)

6.2 Atypical Antipsychotics

6.3 Tricyclic Antidepressants

6.4 Glutamate Modulators

6.5 Investigational Disease-Modifying Therapies

  1. Global Frontotemporal Disorder Treatment Market Sales Analysis by Disease Type ($ Million)

7.1 Behavioral Variant FTD (bvFTD)

7.2 Primary Progressive Aphasia (PPA)

7.3 FTD with Motor Neuron Disease (FTD-MND)

  1. Regional Analysis

8.1   North American Frontotemporal Disorder Treatment Market Sales Analysis – Treatment Type | Drug Class | Disease Type | Country ($ Million)

8.1.1 United States

8.1.2 Canada

8.2   European Frontotemporal Disorder Treatment Market Sales Analysis – Treatment Type | Drug Class | Disease Type | Country ($ Million)

8.2.1 UK

8.2.2 Germany

8.2.3 Italy

8.2.4 Spain

8.2.5 France

8.2.6 Russia

8.2.7 Rest of Europe

8.3   Asia-Pacific Frontotemporal Disorder Treatment Market Sales Analysis – Treatment Type | Drug Class | Disease Type | Country ($ Million)

8.3.1 China

8.3.2 Japan

8.3.3 South Korea

8.3.4 India

8.3.5 Australia & New Zealand

8.3.6 ASEAN Countries

8.3.7 Rest of Asia-Pacific

8.4   Rest of the World Frontotemporal Disorder Treatment Market Sales Analysis – Treatment Type | Drug Class | Disease Type | Country ($ Million)

8.4.1 Latin America

8.4.2 Middle East and Africa

  1. Company Profiles

9.1 AbbVie Inc.

9.1.1 Quick Facts

9.1.2 Company Overview

9.1.3 Product Portfolio

9.1.4 Business Strategies

9.2 Alector, Inc.

9.2.1 Quick Facts

9.2.2 Company Overview

9.2.3 Product Portfolio

9.2.4 Business Strategies

9.3 Anavex Life Sciences Corp.

9.3.1 Quick Facts

9.3.2 Company Overview

9.3.3 Product Portfolio

9.3.4 Business Strategies

9.4 AstraZeneca PLC

9.4.1 Quick Facts

9.4.2 Company Overview

9.4.3 Product Portfolio

9.4.4 Business Strategies

9.5 AviadoBio Ltd.

9.5.1 Quick Facts

9.5.2 Company Overview

9.5.3 Product Portfolio

9.5.4 Business Strategies

9.6 Biogen Inc.

9.6.1 Quick Facts

9.6.2 Company Overview

9.6.3 Product Portfolio

9.6.4 Business Strategies

9.7 Cognition Therapeutics, Inc.

9.7.1 Quick Facts

9.7.2 Company Overview

9.7.3 Product Portfolio

9.7.4 Business Strategies

9.8 Denali Therapeutics

9.8.1 Quick Facts

9.8.2 Company Overview

9.8.3 Product Portfolio

9.8.4 Business Strategies

9.10 Eisai Co., Ltd.

9.10.1 Quick Facts

9.10.2 Company Overview

9.10.3 Product Portfolio

9.10.4 Business Strategies 

9.9 Eli Lilly and Company (Prevail Therapeutics)

9.9.1 Quick Facts

9.9.2 Company Overview

9.9.3 Product Portfolio

9.9.4 Business Strategies

9.11 GSK plc

9.11.1 Quick Facts

9.11.2 Company Overview

9.11.3 Product Portfolio

9.11.4 Business Strategies

9.12 Johnson & Johnson (Janssen Pharmaceuticals)

9.12.1 Quick Facts

9.12.2 Company Overview

9.12.3 Product Portfolio

9.12.4 Business Strategies

9.13 Lundbeck A/S

9.13.1 Quick Facts

9.13.2 Company Overview

9.13.3 Product Portfolio

9.13.4 Business Strategies

9.14 Otsuka Pharmaceutical Co., Ltd.

9.14.1 Quick Facts

9.14.2 Company Overview

9.14.3 Product Portfolio

9.14.4 Business Strategies

9.15 Passage Bio, Inc.

9.15.1 Quick Facts

9.15.2 Company Overview

9.15.3 Product Portfolio

9.15.4 Business Strategies

9.16 Pfizer Inc.

9.16.1 Quick Facts

9.16.2 Company Overview

9.16.3 Product Portfolio

9.16.4 Business Strategies

9.17 Roche Holding AG

9.17.1 Quick Facts

9.17.2 Company Overview

9.17.3 Product Portfolio

9.17.4 Business Strategies

9.18 Sanofi S.A. (Sanofi Genzyme)

9.18.1 Quick Facts

9.18.2 Company Overview

9.18.3 Product Portfolio

9.18.4 Business Strategies

9.19 Takeda Pharmaceutical Company

9.19.1 Quick Facts

9.19.2 Company Overview

9.19.3 Product Portfolio

9.19.4 Business Strategies

9.20 Transposon Therapeutics, Inc.

9.20.1 Quick Facts

9.20.2 Company Overview

9.20.3 Product Portfolio

9.20.4 Business Strategies

9.21 UCB S.A.

9.21.1 Quick Facts

9.21.2 Company Overview

9.21.3 Product Portfolio

9.21.4 Business Strategies

9.22 Viatris Inc.

9.22.1 Quick Facts

9.22.2 Company Overview

9.22.3 Product Portfolio

9.22.4 Business Strategies

9.23 Wave Life Sciences Ltd.

9.23.1 Quick Facts

9.23.2 Company Overview

9.23.3 Product Portfolio

9.23.4 Business Strategies

1. Global Frontotemporal Disorder Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

2. Global Frontotemporal Disorder Pharmacological Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

3. Global Frontotemporal Disorder Non-Pharmacological Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

4. Global Frontotemporal Disorder Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

5. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

6. Global Atypical Antipsychotics Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

7. Global Tricyclic Antidepressants Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

8. Global Glutamate Modulators Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

9. Global Investigational Disease-Modifying Therapies Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

10. Global Frontotemporal Disorder Treatment Market Research and Analysis by Disease Type, 2025–2035 ($ Million)

11. Global Behavioral Variant FTD Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

12. Global Primary Progressive Aphasia Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

13. Global FTD with Motor Neuron Disease Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

14. Global Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

15. North America Frontotemporal Disorder Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)

16. North America Frontotemporal Disorder Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

17. North America Frontotemporal Disorder Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

18. North America Frontotemporal Disorder Treatment Market Research and Analysis by Disease Type, 2025–2035 ($ Million)

19. Europe Frontotemporal Disorder Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)

20. Europe Frontotemporal Disorder Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

21. Europe Frontotemporal Disorder Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

22. Europe Frontotemporal Disorder Treatment Market Research and Analysis by Disease Type, 2025–2035 ($ Million)

23. Asia-Pacific Frontotemporal Disorder Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)

24. Asia-Pacific Frontotemporal Disorder Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

25. Asia-Pacific Frontotemporal Disorder Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

26. Asia-Pacific Frontotemporal Disorder Treatment Market Research and Analysis by Disease Type, 2025–2035 ($ Million)

27. Rest of the World Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

28. Rest of the World Frontotemporal Disorder Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

29. Rest of the World Frontotemporal Disorder Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)

30. Rest of the World Frontotemporal Disorder Treatment Market Research and Analysis by Disease Type, 2025–2035 ($ Million)

1. Global Frontotemporal Disorder Treatment Market Share by Treatment Type, 2025 vs 2035 (%)

2. Global Frontotemporal Disorder Pharmacological Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

3. Global Frontotemporal Disorder Non-Pharmacological Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

4. Global Frontotemporal Disorder Treatment Market Share by Drug Class, 2025 vs 2035 (%)

5. Global Selective Serotonin Reuptake Inhibitors (SSRIs) Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

6. Global Atypical Antipsychotics Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

7. Global Tricyclic Antidepressants Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

8. Global Glutamate Modulators Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025 vs 2035 (%)

9. Global Investigational Disease-Modifying Therapies Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025 vs 2035 (%)

10. Global Frontotemporal Disorder Treatment Market Share by Disease Type, 2025 vs 2035 (%)

11. Global Behavioral Variant FTD Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

12. Global Primary Progressive Aphasia Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

13. Global FTD with Motor Neuron Disease Frontotemporal Disorder Treatment Market Research and Analysis by Region, 2025 Vs 2035 (%)

14. Global Frontotemporal Disorder Treatment Market Share by Region, 2025 Vs 2035 (%)

15. United States Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

16. Canada Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

17. UK Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

18. France Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

19. Germany Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

20. Italy Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

21. Spain Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

22. Russia Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

23. India Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

24. China Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

25. Japan Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

26. South Korea Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

27. Australia & New Zealand Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

28. ASEAN Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

29. Rest of Asia-Pacific Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

30. Latin America Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

31. Middle East & Africa Frontotemporal Disorder Treatment Market Size, 2025-2035 ($ Million)

Choose License Type
    On Discount
Enterprise Custom
  • Printable version
  • No restriction to number of users within the company
CONTACT SALES

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The market was valued at $414.1 million in 2025 and is projected to reach $785.4 million by 2035.
The market is expected to grow at a CAGR of 6.8% during the forecast period (2026–2035).
The pharmacological treatment segment dominates due to the widespread use of antidepressants and antipsychotics.
North America, particularly the United States, leads due to advanced healthcare infrastructure and high R&D investment.
Key trends include increasing R&D investment, growth in disease-modifying therapies, and rising demand for early diagnosis and treatment.